Read More Dividends Earnings News If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today By Benzinga Insights December 28, 3:33 PM Mastercard (NYSE:MA) has outperformed the market over the past 5 years by 10.62% on an annualized basis producing… MA
Read More Biotech General News Enlivex Receives Regulatory Authorization For The Initiation Of A Placebo-Controlled Phase I/II Trial Evaluating Allocetra In Up To 46 Patients With Thumb Osteoarthritis By Benzinga Newsdesk June 3, 8:43 AM First study of AllocetraTM in thumb osteoarthritis, a debilitating disease that affects millions of people in the U.S., and has no FDA-approved therapy Third study of AllocetraTM in osteoarthritis, following ENLV
Read More Analyst Ratings News Price Target Northland Capital Markets Maintains Outperform on PolarityTE, Lowers Price Target to $1 By Benzinga Newsdesk December 28, 12:06 PM Northland Capital Markets analyst Carl Byrnes maintains PolarityTE (NASDAQ:PTE) with a Outperform and lowers the price target from $1.25 to $1. PTE
Read More M&A Movers News Small Cap Tech Trading Ideas Here’s Why Hollysys Shares Are Trading Higher Premarket By Anusuya Lahiri July 8, 8:48 AM The buyer consortium led by Recco Control Technology Pte Ltd and Dazheng Group (Hong Kong) Investment Holdings Company Limited reaffirmed its… HOLI